Kardigan, Inc. (KARD) vs Nektar Therapeutics (NKTR)
A side-by-side comparison of Kardigan, Inc. and Nektar Therapeutics across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
KARD
Kardigan, Inc.
$14.18HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
NKTR
Nektar Therapeutics
$40.12HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
Total return — KARD vs NKTR
growth of $100 · dividends reinvested · last 1yKARD -30.7% (-30.7%/yr)NKTR -24.9% (-24.9%/yr)NKTR compounded faster over this window
KARD NKTR
KARD vs NKTR: by the numbers
- •KARD is the larger company ($1.27B vs $1.15B market cap).
- •Both run net losses; KARD's is the smaller (0.00% vs -287.84% net margin).
Metrics side by side
Valuation
| Metric | KARD | NKTR |
|---|---|---|
| P/S ratio | N/A | 21.08 |
| P/B ratio | 2.06 | 1.27 |
Profitability
| Metric | KARD | NKTR |
|---|---|---|
| Gross margin | 0.00% | 99.36% |
| Operating margin | 0.00% | -240.38% |
| Net margin | 0.00% | -287.84% |
| ROE | N/A | -17.40% |
| ROIC | -57.11% | -12.53% |
Growth (annualized)
| Metric | KARD | NKTR |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -12.34% |
| Total return CAGR (5Y) | N/A | -30.33% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.